Your session is about to expire
← Back to Search
Calcium Channel Blocker
A first, then B for High Blood Pressure
Phase 4
Waitlist Available
Led By Dempsey Hughes, MD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up endpoints will be measured before the first dose of either amlodipine or chlorthalidone and at the end of each six-week double-blinded treatment period
Awards & highlights
Study Summary
This trial is testing two different medications to see which is more effective in lowering blood pressure for liver transplant patients.
Eligible Conditions
- High Blood Pressure
- Liver Transplant
- Kidney Dysfunction
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ endpoints will be measured before the first dose of either amlodipine or chlorthalidone and at the end of each six-week double-blinded treatment period
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~endpoints will be measured before the first dose of either amlodipine or chlorthalidone and at the end of each six-week double-blinded treatment period
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in central aortic pressure at 6 weeks of therapy compared to baseline values
Secondary outcome measures
Change in Blood pressure
Change in Renal function
Number of patients with improvement in diastolic function (E/e' ratio)
+1 moreTrial Design
2Treatment groups
Active Control
Group I: A first, then BActive Control2 Interventions
6 weeks of drug A followed by a 2-week washout period completed with 6 weeks of drug B
Group II: B first, then AActive Control2 Interventions
6 weeks of drug B followed by a 2-week washout period completed with 6 weeks of drug A
Find a Location
Who is running the clinical trial?
American Society for TransplantationUNKNOWN
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,814 Previous Clinical Trials
47,290,875 Total Patients Enrolled
Northwestern UniversityLead Sponsor
1,576 Previous Clinical Trials
911,922 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have had a heart attack or a procedure to improve blood flow to your heart within the past 60 days.You are allergic to sulfa drugs.
Research Study Groups:
This trial has the following groups:- Group 1: A first, then B
- Group 2: B first, then A
Awards:
This trial has 3 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Could you please provide an estimate of the total number of individuals involved in this clinical experiment?
"Affirmative, the information on clinicaltrials.gov attests to this study's current recruitment campaign which began on July 12th, 2022 and was recently updated a day later. 15 participants are expected from one location."
Answered by AI
How would you rate the security of individuals when using A prior to B?
"With the Phase 4 trial indicating that both A and B have been approved, our team at Power gave them a safety rating of 3 out of three."
Answered by AI
Is enrollment in this trial still open to volunteers?
"Per the information published on clinicaltrials.gov, this trial is currently recruiting participants since its July 12th 2022 posting date and latest edit of July 13th 2022."
Answered by AI
Recent research and studies
Share this study with friends
Copy Link
Messenger